In vitro cell model of acquired resistance to EGFR TKIs was established by culturing sensitive EGFR-mutant lung cancer HCC827 or PC9 cells in gefitinib or osimertinib with elevating concentration as we previously reported (12). Here, EGFR is linked to lung carcinoma.